603998 方盛製藥
按盤價 
12.220 -0.130 (-1.053%) | 2024/09 - 九個月 人民幣(K¥) | 與去年同期 比較 | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | 2020/12 人民幣(K¥) | ||
| 營業總收入 | 1,347,963 | 10.95% | 1,628,542 | 1,792,001 | 1,566,973 | 1,278,765 | |
| 減：營業總成本 | 1,150,515 | 6.95% | 1,474,391 | 1,647,426 | 1,458,357 | 1,190,072 | |
| 其中:營業成本 | 365,895 | -2.43% | 519,538 | 586,285 | 563,272 | 463,709 | |
| 財務費用 | 6,715 | -10.38% | 10,818 | 19,930 | 17,654 | 13,701 | |
| 資產減值損失 | (2,093) | -819.34% | (2,334) | (1,179) | (11,944) | (5,566) | |
| 公允價值變動收益 | 51 | -30.46% | 49 | (63) | 127 | 15 | |
| 投資收益 | 41,982 | 735.57% | (3,851) | 166,247 | (9,589) | (18,747) | |
| 其中：對聯營企業和合營企業的投資收益 | (2,194) | -44.44% | (4,179) | (4,777) | (1,454) | (19,486) | |
| 營業利潤 | 249,016 | 56.28% | 196,446 | 332,039 | 99,694 | 72,375 | |
| 利潤總額 | 249,980 | 57.70% | 203,338 | 326,575 | 90,791 | 68,972 | |
| 減：所得稅費用 | 22,583 | 26.20% | 23,714 | 49,869 | 20,870 | 15,195 | |
| 淨利潤 | 227,397 | 61.71% | 179,624 | 276,705 | 69,921 | 53,777 | |
| 減：非控股權益 | (742) | -46.22% | (7,199) | (9,148) | (119) | (10,017) | |
| 股東淨利潤 | 228,138 | 60.66% | 186,823 | 285,853 | 70,041 | 63,794 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.530 | 60.61% | 0.430 | 0.660 | 0.160 | 0.150 | |
| 每股派息 (元) * | 0.050 | -44.44% | 0.290 | 0.350 | 0.150 | 0.120 | |
| 每股淨資產 (元) * | 3.632 | 12.30% | 3.316 | 3.162 | 2.785 | 2.682 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 05/11/2024 10:39 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
